TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients \> 18 years of age~* OAB symptoms for \> 3 months~* Symptoms defined as greater than 3 episodes/week of an uncontrolled urge to void causing incontinence.~* May or may not be accompanied by urinary frequency~* May be accompanied by stress urinary incontinence where stress incontinence does not predominate~Exclusion Criteria:~* Male Patients~* Underlying cortical or spinal cord pathology including SCI, MS, or~* Parkinson's Disease~* Urinary retention with post-void residual \> 150cc~* Current treatment or treatment within the last 3 months with anticholinergic medications~* Patients not able to complete the questionaires or voiding diaries in English~* Pregnancy~* Active urinary tract infections~* Bladder Cancer or unevaluated hematuria~* Known diagnosis of narrow angle glaucoma~* Severe constipation~* History of reduced renal function (CrCl\<30ml/min)~* History of liver disease~* Current treatment with cytochrome P450 inhibitor medications

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vesicare (Type: ACTIVE_COMPARATOR): Vesicare alone
- Vesicare/behavioral modification (Type: ACTIVE_COMPARATOR): Vesicare plus behavioral modification

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Treatment for Great Toe Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with grade 2 hallux rigidus using the grading system described by Coughlin and Shurnas.8~* Patients older than 18 and less than 88 years of age~* Patients will have the ability to perform the questionnaires and will complete the informed consent process.~Exclusion Criteria:~* Patients with the diagnosis of gout or inflammatory arthropathy~* Patients with inadequate bone stock of the 1st MTP joint (large bone cyst \>1 cm, avascular necrosis)~* Allergy to polyvinyl alcohol~* Anyone unable to commit to follow up appointments~* Patients with significant medical comorbidities that make them unsuitable for elective surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 88 Years
- Healthy Volunteers: f

Study Arms:
- Cartiva Hemiarthroplasty (Type: ACTIVE_COMPARATOR): Cartiva implant
- Cheilectomy (Type: ACTIVE_COMPARATOR): Bone spur removal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients and/or their legal representative must be able to understand the study and voluntarily sign the ICF~2. Patients age \<18 years~3. Patients who are able to adhere to protocol requirements~4. Patients who are expected to require PN for at least 7 days~5. Premature infants (\<36 weeks of gestation) require at least 80% PN to meet nutrition requirements at study entry; full term infants and children require at least 70% PN to meet nutrition requirements at study entry~Exclusion Criteria:~1. Patients who are not expected to survive hospitalization or with a severe illness with foreseeable intercurrent events that could jeopardize the patient's participation in the study~2. Patients with a known hypersensitivity to lipid emulsion, egg or soybean proteins, or any of the active substances, excipients, or components of the container~3. Patients with a diagnosis of shock, renal failure requiring dialysis, or severe metabolic acidosis (eg, pH \<7.10, serum bicarbonate level ≤15 mEq/L , and/or an Anion Gap \>16 mEq/L)~4. Patients with hemodynamic instability as judged by the Investigator~5. Patients with uncorrected metabolic disorders (eg, diabetes) or liver disease including cholestasis~6. Patients with severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (triglyceride \>400 mg/dL)~7. Patients who are unable to tolerate the necessary laboratory monitoring~8. Patients who have a new and active infection (as assessed by the investigator) at time of initiation of study treatment~9. Patients who are enrolled in another clinical trial involving an investigational agent~10. Patients who were treated with IV lipids within 48 hours of randomization into the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Clinolipid (lipid injectable emulsion, USP) 20% (Type: EXPERIMENTAL): Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
- Intralipid 20% (lipid injectable emulsion, USP) (Type: ACTIVE_COMPARATOR): Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed transitional cell carcinoma of the urinary bladder.~* Metastatic or locally advanced disease.~* No prior chemotherapy.~* Performance status (World Health Organization) 0-2.~* Measurable or evaluable disease.~* Measurable disease is defined as at least 1 unidimensional measurable lesion~  ≥20 mm by conventional techniques or 1 bidimensionally measurable lesion ≥ 20 X 10 mm. Lesions that are smaller or uni- or bidimensionally unmeasurable are considered as evaluable disease.~* Adequate liver (bilirubin ≤ 1.5 Upper Normal Limit, serum glutamate-pyruvate aminotransferase/serum glutamic pyruvic transaminase ≤ 2 Upper Normal Limit, ALP ≤ 2.5 Upper Normal Limit), renal (creatinine ≤ 1.5 Upper Normal Limit) and bone marrow (absolute neutrophil count ≥ 1,500/mm3, platelet count ≥ 100,000/mm3) function.~* Life expectancy \> 3 months.~* Patients must be able to understand the nature of this study and give written informed consent.~Exclusion Criteria:~* History of serious cardiac disease (unstable angina, severe congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias).~* Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer.~* Active infection.~* Uncontrolled inflammation.~* Pregnant or lactating women.~* Psychiatric illness or social situation that would preclude study compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MVAC -\> GEM+CDDP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence Endoscopy of Esophageal Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced esophageal carcinoma (cT1b-4a N0-3 M0) in multi-disciplinary esophageal oncology meeting agreed on long course neoadjuvant chemoradiotherapy, followed by esophagectomy;~* Age ≥ 18 years;~* Written informed consent.~Exclusion Criteria:~* Patients with psychological diseases or medical issues who are not able to sign informed consent form;~  * Concurrent uncontrolled medical conditions;~ * Pregnancy or breast feeding. A negative pregnancy test must be available for women of childbearing potential (i.e. premenopausal women with intact reproductive organs and women less than two years after menopause);~ * Irradical endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) of primary tumor prior to start of neoadjuvant chemoradiotherapy~ * Received a different investigational drug within 30 days prior to the dose of bevacizumab-800CW;~ * History of infusion reactions to bevacizumab or other monoclonal antibodies;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NIR endoscopy with 4.5 mg bevacizumab-800CW (Type: EXPERIMENTAL): A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals.
- NIR endoscopy with 10 mg bevacizumab-800CW (Type: EXPERIMENTAL): A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals.
- NIR endoscopy with 25 mg bevacizumab-800CW (Type: EXPERIMENTAL): A non-randomized, non-blinded, prospective, feasibility study.~* IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~* Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Silver Impregnated Dressings to Reduce Wound Complications in Obese Patients at Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing cesarean section (with or without concurrent tubal ligation)~* Body mass index (based on most recent weight) \>=30~Exclusion Criteria:~* Known allergy to silver~* Less than 18 years of age~* Preoperative evidence of current abdominal wall infection~* Contraindication to closure of the skin at time of surgery~* Plan to perform procedures in addition to cesarean section (with or without tubal ligation)~* Patients with previously placed abdominal wall mesh at site of planned surgery~* Inability to participate in medical decision making~* Inability to follow up with the Michigan Visiting Nurses or are unable to return to the University of Michigan Medical Center for staple removal

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard Dressing (Type: PLACEBO_COMPARATOR): Obese patients undergoing cesarean section in this arm will receive a standard island-type dressing
- Silverlon (Type: EXPERIMENTAL): Obese patients undergoing cesarean section in this arm will receive Silverlon, a silver impregnated dressing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predicting Medication Response for Autoimmune Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis diagnosis~* On or about to begin a treatment for condition above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ulcerative Colitis (Type: None): None
- Crohn's Disease (Type: None): None
- Rheumatoid Arthritis (Type: None): None
- Psoriasis (Type: None): None
- Control (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Alteplase for Blood Flow Restoration in Hemodialysis Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults \> 18 yrs old~2. Hemodialysis patients~3. Vascular access with a permanent catheter~4. No prior rt-PA use in the catheter over the previous 21 days~5. One rt-PA instillation per catheter (i.e. we will only document the results of 1 rt-PA instillation per catheter. Numerous rt-PA instillations in the same catheter will NOT be considered new events, and not entered into the study)~Exclusion Criteria:~1. Critically ill patients in the ICU setting.~2. Contraindications / cautions with alteplase use including: known hypersensitivity to alteplase or its components (l-arginine, phosphoric acid, polysorbate 80), patients with known conditions associated with bleeding events (e.g.intracranial bleed in last 4 weeks, major hemorrhage in last 4 weeks (Hgb drop of 20 g/L)), recent surgery (\<48 hours), recent biopsy (\<48 hours), hemostatic defects including severe hepatic disease, or current intracranial / intraspinal neoplasm.~3. Hemodialysis catheter has been in the patient less than 14 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Alteplase used by normal dwell procedure
- 2 (Type: EXPERIMENTAL): Alteplase given by an new push protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients are eligible if they have histologically proven adenocarcinoma, are planning to or currently undergoing treatment with an anti-EGFR (epidermal growth factor receptor) therapy, and are 18 years of age or older.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial on Effectiveness of ACTs in Ghana

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients aged 6 months to 59 months~* Absence of severe malnutrition~* A slide-confirmed P. falciparum asexual parasitaemia between 2,000/µl and 200,000/µl~* A measured axillary temperature ≥ 37.5 °C or rectal/tympanic temperature ≥ 38.0 °C~* Absence of general danger signs (unable to drink; repeated vomiting; recent history of convulsions; lethargic or unconscious state; unable to stand up or to sit)~* Ability to tolerate oral therapy~* Permanent residence in study area~* Informed consent by the legal representative of the subject, if possible, the parents~Exclusion Criteria:~* Adequate anti-malarial treatment within the previous 7 days~* Antibiotic treatment for a current infection~* Previous participation in a clinical trial~* Haemoglobin \< 5 g/dl~* Leucocyte count: \> 15000/µl~* Mixed plasmodial infection~* Severe malaria as defined by WHO recommendations~* Any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known HIV infection) or concomitant disease masking assessment of response~* History of allergy or intolerance against trial medication

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- AL (Type: EXPERIMENTAL): Artemether plus Lumefantrine 6 dose 3 days treatment
- ASAQ (Type: ACTIVE_COMPARATOR): Artesunate plus Amodiaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 18 years~* New Diagnosis of Bcr-Abl positive ALL or Bcr-Abl negative ALL~* Receiving induction chemotherapy with the standard Princess Margaret Hospital modified DFCI protocol~* Will have a functioning central venous access catheter in-situ~* Agreeing to participate in the study and sign the informed consent form~Exclusion Criteria:~* Concomitant use of other agents that inhibit hepatic cytochrome CYP3A4, as these drugs may alter vincristine and imatinib levels~* Elevated liver function tests: bilirubin \>1.5xULN or AST/ALT \>2.5xULN, or documented history of chronic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bcr-Abl positive ALL (Type: None): None
- Bcr-Abl negative ALL (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Granulomatosis with polyangiitis or microscopic polyangiitis (according to Chapel Hill criterions), with or without detectable ANCA~* Decision taken to start an induction regimen with rituximab~* Informed and having signed the study consent form~* If of child-bearing potential, female patients will have use an effective method of contraception during RTX (rituximab) treatment and in the 12 months following RTX treatment stop~* no-breast-feeding during RTX treatment and in the 12 months following RTX treatment stop~Exclusion Criteria:~* Other primary or secondary systemic vasculitis~* Incapacity or refusal to sign the informed consent form~* Incapacity or refusal to adhere to treatment or perform the follow-up examinations required by the study~* Allergy, documented hypersensitivity or contraindication to the medications used in the present study (corticosteroids, rituximab)~* severe active infection~* Patient with severe heart failure (stage NYHA IV) or any other unstable heart disease Pregnancy, except for cases where the expected benefit oj treatment seems to surpass the potential risks~* Patients with active hepatitis B~* Any live vaccine within four weeks prior to the first infusion of RTX

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: None): a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/m² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fever Algorithm Development of a Non-invasive Wearable Core Body Temperature Sensor System in Intensive Care Unit Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years old.~* Patients which are treated at the cardiosurgical and vascular intensive care unit of the University Hospital Zurich.~* Expected length of stay in the intensive care unit at least 24 hours~* Clinical standard monitoring including an invasive CBT measurement (e.g. blood temperature from a pulmonary catheter if present or from a vesical catheter routinely placed)~* Informed consent signed by the patient~Exclusion Criteria:~* Acute medical contraindications against the measurement of the non-invasive wearable device (e.g. skin diseases) and band-aid allergies.~* Implanted pacemakers or other implanted life sustaining devices~* Comatose state of the patient~* Pregnant Women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Unobtrusive data collection (Type: OTHER): Unobtrusive data collection using noninvasive sensor systems.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility